Shares of uniQure (NASDAQ:QURE – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $18.60.
QURE has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of uniQure in a research report on Tuesday, August 20th. StockNews.com upgraded uniQure to a “sell” rating in a report on Monday, August 5th. The Goldman Sachs Group upped their target price on uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $24.00 price target on shares of uniQure in a research note on Tuesday, July 16th.
Read Our Latest Research Report on uniQure
Institutional Inflows and Outflows
uniQure Stock Up 1.3 %
uniQure stock opened at $5.54 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.36 and a quick ratio of 7.36. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The company’s 50-day moving average is $6.93 and its 200 day moving average is $5.65.
uniQure (NASDAQ:QURE – Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.08. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $3.47 million. Equities research analysts anticipate that uniQure will post -4.04 earnings per share for the current fiscal year.
uniQure Company Profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Featured Stories
- Five stocks we like better than uniQure
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Leveraged ETFs to Multiply Returns
- Breakout Stocks: What They Are and How to Identify Them
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Short Selling: How to Short a Stock
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.